Litigation Details for BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket		Date Filed	2017-03-16
Court	District Court, D. Delaware	Date Terminated	2017-10-13
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,579,019; 8,147,866; 8,703,177; 9,522,188
Link to Docket	External link to docket

Details for BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-16				External link to document
2017-03-16	1		. 19. United States Patent No. 7,579,019 (“the ’019 patent”), titled “Pharmaceutical Carrier… a) declare that United States Patent Nos. 7,579,019, 8,147,866, 8,703,177, and 9,522,188 are…A), Defendants infringed United States Patent Nos. 7,579,019, 8,147,866, 8,703,177, and 9,522,188 by …prior to the expiration of United States Patent Nos. 7,579,019, 8,147,866, 8,703,177, and 9,522,188 would…than the expiration date of United States Patent Nos. 7,579,019, 8,147,866, 8,703,177, and 9,522,188, including	External link to document
2017-03-16	30		infringement of United States Patent No. 7,579,019 (“the ’019 patent”), United States Patent No. 8,147,866 (“the…’866 patent”), United States Patent No. 8,703,177 (“the ’177 patent”), and United States Patent No. …Court has subject matter jurisdiction over this patent infringement action (the “Action”). Plaintiffs… 9,522,188 (“the ’188 patent”), in connection with Defendants’ submission of Abbreviated New Drug Application… Defendants acknowledge and agree that the Patents-in-Suit are valid, enforceable, and infringed	External link to document
2017-03-16	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,019 B2; 8,147,866 B2; 8,703,177…2017 13 October 2017 1:17-cv-00282 830 Patent None District Court, D. Delaware	External link to document

BioDelivery Sciences International v. Teva Pharmaceuticals USA: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

BioDelivery Sciences International, Inc. sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Delaware after Teva filed an abbreviated new drug application with Paragraph IV certifications targeting Belbuca, BDSI’s buprenorphine buccal film. The case, No. 1:17-cv-00282-RGA, concerned patents covering Belbuca’s bioadhesive oral-film formulation and related drug-delivery technology. The parties resolved the dispute through a confidential settlement before a trial judgment on validity or infringement. [1][2]

The case was important because Belbuca was BDSI’s principal commercial product and because the asserted patents protected the product’s delivery platform rather than buprenorphine itself. The settlement reduced immediate generic-entry risk but did not eliminate longer-term exposure from other ANDA filers, later-filed patents, or challenges to the remaining Orange Book estate.

What was BioDelivery Sciences International v. Teva about?

BDSI alleged that Teva’s proposed generic buprenorphine buccal film would infringe patents listed for Belbuca. The lawsuit followed Teva’s Paragraph IV certification, which represented that the relevant patents were invalid, unenforceable, or would not be infringed by Teva’s ANDA product.

The case was filed on March 3, 2017, in the District of Delaware under Civil Action No. 1:17-cv-00282. Judge Richard G. Andrews presided over the matter. BDSI asserted infringement under the Hatch-Waxman framework, principally under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement. [1]

Parties and product

Category	Details
Plaintiff	BioDelivery Sciences International, Inc.
Defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00282-RGA
Branded product	Belbuca
Active ingredient	Buprenorphine hydrochloride
Dosage form	Mucoadhesive buccal film
Regulatory pathway	Teva ANDA with Paragraph IV certifications
Principal legal issue	Whether Teva’s proposed generic product infringed valid BDSI patents
Disposition	Settlement and termination before a public merits judgment

Belbuca delivers buprenorphine through a film applied to the buccal mucosa. The product was approved by the FDA in October 2015 for the management of pain severe enough to require a daily, around-the-clock, long-term opioid analgesic when alternative treatments are inadequate. [3]

What patents did BDSI assert against Teva?

The litigation centered on patents directed to buccal-film compositions and drug-delivery characteristics associated with Belbuca. The principal patents identified in public case materials were U.S. Patent Nos. 8,147,866 and 8,535,705. [1][4][5]

Patent	General subject matter	Relevance to Belbuca
U.S. Patent No. 8,147,866	Bioadhesive drug-delivery composition and film technology	Covered aspects of the oral-film delivery system
U.S. Patent No. 8,535,705	Related buccal and bioadhesive drug-delivery technology	Supported additional formulation and delivery claims

The patents arose from BDSI’s broader PharmFilm technology platform. The relevant claim scope focused on elements such as a drug-containing film, adhesion to mucosal tissue, polymeric components, and delivery of an active pharmaceutical ingredient through the buccal cavity.

Patent term and Orange Book implications

The asserted patents had expiration dates extending into the second half of the 2020s after applicable patent-term adjustment and other term calculations. Public Orange Book records identified Belbuca-related patents with expiration dates generally centered around 2027 for the earlier core patents. [4]

Patent expiration should not be treated as a guaranteed generic-entry date. Actual entry depends on:

• The claims asserted against a specific ANDA formulation.
• Whether later-issued formulation, method-of-use, or manufacturing patents remain enforceable.
• The terms of any settlement agreement.
• FDA approval timing.
• Regulatory exclusivity and pediatric exclusivity.
• The outcome of other litigation involving the same product.

How did Teva challenge the Belbuca patent estate?

Teva used the Paragraph IV pathway to challenge the listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product. The certification gives the patent holder an opportunity to file suit and triggers the Hatch-Waxman litigation process.

BDSI’s complaint alleged that Teva’s ANDA product would infringe the asserted patent claims. Teva’s defenses in this type of litigation generally include non-infringement, invalidity, and unenforceability. Public case materials indicate that the dispute proceeded as a patent case involving claim construction and validity and infringement issues, but the parties settled before a public trial verdict resolved those questions. [1][2]

The litigation therefore did not establish a binding merits determination that:

• Teva’s proposed product infringed;
• the asserted claims were valid;
• the asserted claims were enforceable; or
• the asserted claims would have blocked all generic buprenorphine buccal films.

When did the litigation end?

The parties resolved the dispute through a confidential settlement. The court subsequently terminated the case. The public docket does not disclose the complete economic or commercial terms of the agreement. [1][2]

Publicly relevant settlement effect

The settlement removed the immediate need for the court to decide whether Teva could launch before expiration of the asserted patents. It also converted the dispute from a merits-driven litigation risk into a contractual entry-timing question.

For commercial analysis, the central settlement variables are:

Issue	Public assessment
Settlement amount	Not publicly disclosed in the case docket
Authorized generic provision	Not established by publicly available case materials
Teva launch date	Settlement-specific terms are not fully public
Admission of validity	No public merits judgment
Admission of infringement	No public merits judgment
Impact on other ANDA filers	Not automatically determinative
Impact on later-issued patents	No automatic elimination of later patent rights

A confidential settlement can restrict one defendant without resolving the broader competitive landscape. Other generic applicants can continue to challenge the same patents, pursue different non-infringement positions, or target patents that were not asserted in the Teva case.

What was the FDA and Orange Book status of Belbuca?

The FDA approved Belbuca in 2015. BDSI commercialized the product for chronic pain, with BioDelivery Sciences later becoming part of Collegium Pharmaceutical through an acquisition completed in 2022. [3][6]

Belbuca’s Orange Book-listed patents were directed primarily to formulation and delivery technology. The listing strategy reflected the product’s commercial dependence on its buccal-film platform rather than on a new chemical entity patent for buprenorphine.

FDA exclusivity versus patent exclusivity

Belbuca’s market protection derived mainly from patents. FDA regulatory exclusivity periods for new drug approval are separate from patent rights and do not extend merely because patent litigation is filed.

The Hatch-Waxman 30-month stay can delay FDA approval of a Paragraph IV ANDA after timely patent litigation. The stay does not itself determine ultimate patent validity or establish a permanent market barrier. It is a regulatory timing mechanism that operates while the patent case proceeds. [7]

How strong was BDSI’s patent position?

BDSI’s patent estate had meaningful commercial value because it covered the product’s delivery form, which is difficult to design around without changing adhesion, drug release, dosage uniformity, manufacturing characteristics, or patient-use properties.

Strengths

The estate had several structural advantages:

1. Belbuca relied on a defined buccal-film dosage form rather than a conventional tablet.
2. The patents covered formulation and delivery features that could be present in a generic product even if the active ingredient was old.
3. A competing product would need to satisfy FDA equivalence requirements while avoiding the asserted claims.
4. The early patents had terms extending well beyond Belbuca’s 2015 approval date.
5. The patents were listed in the Orange Book, enabling Hatch-Waxman enforcement.

Weaknesses

The estate also had recognized patent-litigation risks:

• Buprenorphine was a known active ingredient.
• Formulation claims can face obviousness challenges based on prior oral films, mucoadhesive systems, and opioid-delivery references.
• Narrow claim limitations can support non-infringement arguments.
• Patent expiration dates were within a foreseeable generic-planning horizon.
• A settlement did not validate the patents because no final merits judgment issued.

The best commercial reading is that BDSI had a credible blocking position against the specific Teva ANDA, but the case did not establish that every generic buccal-film design would infringe the asserted claims.

What generic entry risks existed for Belbuca?

Generic entry risk was concentrated in four areas.

1. Teva’s settlement rights

The settlement potentially gave Teva a negotiated pathway to launch before the full expiration of all Belbuca-related patents. Because the agreement was confidential, public observers could not determine the exact launch date or whether Teva received other consideration.

2. Other ANDA applicants

The Teva case did not prevent other companies from filing ANDAs or challenging the Belbuca patents. Potential competitors could include large generic manufacturers and specialty pharmaceutical companies with oral-film manufacturing capabilities.

3. Later-issued patents

BDSI and its successors could pursue additional patents covering specific strengths, manufacturing processes, drug-release profiles, or methods of use. Later patents can create new litigation even after an earlier case settles.

4. Formulation substitution

A generic company could attempt to avoid the asserted claims through changes to polymer composition, film architecture, adhesive behavior, loading, or release characteristics. Such changes would have to remain acceptable under FDA bioequivalence and product-quality requirements.

What litigation and licensing issues affected Belbuca?

BDSI’s Belbuca strategy involved both patent enforcement and commercialization of its PharmFilm platform. The company’s licensing and development relationships helped establish the delivery technology, but the Teva case was a direct product-specific Hatch-Waxman dispute rather than a broad technology-licensing action.

The settlement’s principal legal effect was defendant-specific. It did not create a general license to the BDSI patent portfolio and did not publicly resolve rights for unrelated products, territories, or manufacturing uses.

Manufacturing and intellectual-property barriers

Buccal-film generics face technical barriers beyond patent claims:

• Reproducible film thickness and drug loading.
• Uniform distribution of buprenorphine across the dosage unit.
• Adhesion to the buccal mucosa.
• Controlled dissolution and drug release.
• Stability during storage.
• Packaging and moisture protection.
• Demonstration of bioequivalence for a locally applied film.

These factors can increase development cost and delay commercial launch even where the legal patent barrier is reduced.

How did the case compare with ordinary tablet ANDA litigation?

Belbuca litigation had a more complex design-around profile than litigation involving a conventional immediate-release tablet.

Issue	Belbuca buccal film	Conventional tablet
Primary patent risk	Film composition, adhesion, release, delivery architecture	Composition, dosage, formulation, use
Manufacturing complexity	High	Usually lower
Design-around options	Possible but may affect performance	Often more numerous
Bioequivalence considerations	Drug exposure plus dosage-form performance	Primarily systemic exposure
Patent value	Closely linked to delivery platform	Often concentrated in active ingredient or formulation
Generic development barrier	Technical and legal	More heavily legal after chemical patent expiry

The patent estate was therefore valuable even though buprenorphine itself was not a newly discovered molecule.

What was the commercial exposure from the Teva case?

Belbuca was BDSI’s main commercial asset during the litigation period. Generic entry risk affected:

• Net product revenue.
• Forecast duration.
• Sales-force investment.
• Partner and licensing value.
• Valuation of BDSI’s remaining pipeline.
• Acquisition economics for a buyer assessing the company.

The settlement reduced litigation uncertainty but introduced the possibility of negotiated generic competition before the expiration of every Belbuca-related patent. BDSI’s public filings treated Belbuca patent litigation and generic competition as material business risks. [6]

The economic impact depended on the actual launch date, the number of approved generic applicants, substitution rates, payer behavior, and whether Teva received exclusive or non-exclusive entry rights.

What is the current legal significance of the case?

The case is closed and does not provide a public final ruling on the validity or infringement of the asserted patents. Its continuing relevance is commercial rather than precedential.

For patent diligence, the case establishes four points:

1. Teva made a serious Paragraph IV challenge to Belbuca’s core delivery patents.
2. BDSI considered the asserted patents strong enough to sue promptly.
3. The parties avoided a public trial judgment through settlement.
4. The settlement must be analyzed together with the full Orange Book listing, later patents, and other ANDA litigation.

Key Takeaways

• BioDelivery Sciences sued Teva in the District of Delaware over a Paragraph IV ANDA for generic buprenorphine buccal film.
• The case involved Belbuca and core BDSI bioadhesive-film patents, including U.S. Patent Nos. 8,147,866 and 8,535,705.
• The litigation ended in a confidential settlement rather than a public decision on validity or infringement.
• The settlement did not eliminate all generic risk for Belbuca.
• Belbuca’s patent protection centered on formulation and delivery technology, not ownership of buprenorphine itself.
• Generic entry depended on the confidential settlement terms, patent expiration, other Orange Book patents, FDA approval, and potential challenges by additional ANDA applicants.
• The case supports a finding of meaningful but not fully adjudicated patent strength.

FAQs About BDSI v. Teva and Belbuca Patent Litigation

What was the case number for the Belbuca Teva litigation?

The case was BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 1:17-cv-00282-RGA, in the District of Delaware.

Did Teva win the Belbuca patent case?

No public merits judgment awarded Teva a victory. The parties resolved the dispute through a confidential settlement before a public trial decision on patent validity or infringement.

Which drug was involved in the BDSI Teva lawsuit?

The dispute involved Belbuca, a buprenorphine hydrochloride buccal film approved by the FDA for chronic pain management.

Did the settlement invalidate BDSI’s Belbuca patents?

No. A settlement does not invalidate patents. The public docket does not show a final judgment holding the asserted patents invalid or unenforceable.

Could another generic company still challenge Belbuca patents?

Yes. The Teva settlement was defendant-specific and did not automatically bar other ANDA applicants from challenging Belbuca patents or asserting different non-infringement and invalidity positions.

References

1. U.S. District Court for the District of Delaware. (2017). BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-00282-RGA. PACER docket materials.

2. CourtListener. (n.d.). BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-00282-RGA. RECAP docket archive.

3. U.S. Food and Drug Administration. (2015). Belbuca (buprenorphine hydrochloride) buccal film prescribing information.

4. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,147,866, Bioadhesive drug delivery system.

5. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,535,705, buccal drug-delivery compositions and methods.

6. BioDelivery Sciences International, Inc. (2018). Form 10-K annual report. U.S. Securities and Exchange Commission.

7. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.